Stock 2696 SHANGHAI HENLIUS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:13 2024-04-23 am EDT 		5-day change 1st Jan Change
15.26 HKD 0.00% Intraday chart for Shanghai Henlius Biotech, Inc. +3.53% +9.78%
Apr. 17 Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug MT
Apr. 17 Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration CI

Evolution of the average Target Price on Shanghai Henlius Biotech, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c5f297.5Z-zn0fLSSCEMiOBUdayvmiGahEkb9J1sthoyhCMTNQ.lfHf-3GpA0-we0azGLT86jvyU1JKCOcE8esasijuCIWy-ePQEKF_RfxQRA~adf02ca8839249cfd404954f2351a4f1

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
14.11 CNY
Average target price
16.39 CNY
Spread / Average Target
+16.15%
High Price Target
23.05 CNY
Spread / Highest target
+63.37%
Low Price Target
8.352 CNY
Spread / Lowest Target
-40.80%

Consensus detail

Consensus revision (last 18 months)

Ratings for Shanghai Henlius Biotech, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. Consensus Shanghai Henlius Biotech, Inc.